Recent Updates
Recently added Catalysts
RVTY Positive Sentiment Score: 75/100

Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs

Thursday, July 23, 2026 1 min read
Key Takeaway: Revvity, Inc. has announced the development of the T-SPOT™ A201, a high-throughput automated platform aimed at enhancing the accuracy and reliability of T-SPOT.TB™ testing in clinical labs. This innovation is particularly relevant for large-volume labs and addresses the growing demand for tuberculosis testing, driven by factors such as immigration screening and immunosuppressive therapy evaluations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a next-generation automated platform.
  • Supports high-throughput testing for latent tuberculosis.
  • Addresses critical global health challenges effectively.

Full Press Release Details

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the development of the T-SPOT™ A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB™ testing for large-volume clinical labs, enabling a reliable, accurate solution for latent tuberculosis (TB) detection. Tuberculosis remains a critical global health challenge, with testing demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies

Frequently Asked Questions

What is the T-SPOT™ A201 platform?

The T-SPOT™ A201 is a next-generation high-throughput automated platform for TB testing.

What is the purpose of the T-SPOT.TB™ testing?

The T-SPOT.TB™ testing is designed for reliable detection of latent tuberculosis.

Why is TB testing demand increasing?

Demand for TB testing is increasing due to immigration screening and immunosuppressive therapies.

Who will benefit from the T-SPOT™ A201?

Large-volume clinical labs will benefit from the performance advantages of the T-SPOT™ A201.

Tags: RVTY Viatris Investor Conferences Healthcare Revvity T-SPOT.TB tuberculosis clinical labs high-throughput
Last updated: Jul 23, 2026

Biotech snapshot

Cash runway
$860M liquidity · $0M/mo burn
Low dilution risk